Felix Dobbs, Broken String Biosciences CEO

Ex­clu­sive: Backed by Il­lu­mi­na, Bro­ken String Bio­sciences rais­es $15M to find off-tar­get gene ed­its

Bro­ken String Bio­sciences has raised $15 mil­lion for its off-tar­get se­quenc­ing ser­vice for gene edit­ing com­pa­nies.

The Se­ries A round was led by Il­lu­mi­na Ven­tures and Mérieux Eq­ui­ty Part­ners and in­clud­ed HER­AN Part­ners, Ten­cent and Di­eter von Holtzbrinck Ven­tures. Mérieux’s Yoann Bon­namour and Il­lu­mi­na Ven­tures’ Ar­naud Autret have joined Bro­ken String’s board.

Bro­ken String’s se­quenc­ing plat­form ser­vice is tai­lored for gene edit­ing com­pa­nies and their con­tract re­search or­ga­ni­za­tions to find off-tar­get ed­its as they de­vel­op new ther­a­pies.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.